Introduction
Evidence is growing that nocturnal hypersecretion of acid is an important factor in the pathogenesis of duodenal ulcer, as originally proposed by Dragstedt and Owens.' Pharmacological studies performed by Gledhill et al comparing a single 800 mg dose of cimetidine given at night with 400 mg given twice daily showed that both dosage regimens were equally effective in reducing mean 24 hour intragastric acidity and that nocturnal secretion of acid was significantly better controlled with cimetidine 800 mg at night than with the twice daily regimen. 2 On the basis of these findings they suggested that a single night time dose should be evaluated in a clinical trial. Results of an open randomised clinical trial of cimetidine 800 mg were recently published and showed that healing rates and duration of treatment were not different when cimetidine was given as 800 mg once daily or as 400 mg twice daily. 3 The purpose of our multicentre study was to investigate in a double blind fashion the safety and efficacy of cimetidine 800 mg once daily compared with 400 mg twice daily in patients with duodenal ulceration.
Patients and methods
Seven centres particip?;te-;n this study. Patients with duodenal ulcer confirmed endoscopically within the previous four days were randomly allocated by a double dummy technique to receive cimetidine twice daily (one 400 mg tablet at breakfast and one 400 mg tablet at bedtime) or once daily (two 400 mg tablets at bedtime). Treatment was continued for four weeks, at the end of which patients were re-examined endoscopically. During the treatment period all other drugs for peptic ulceration were stopped except for a specific antacid to be taken solely for relief of pain not controlled by cimetidine. After two and four weeks the paticnts were examined clinically and interviewed about the occurrence of adverse reactions; details were obtained on ulcer pain and consumption of antacids, which they had previously recorded on diary cards.
Results
At a previously determined date 197 patients were eligible for entry into the stu-dy; of these, 187 were eligible for analysis after four weeks. Ninety one received the once daily dosage and 96 the twice daily dosage. Ten patients did not complete the study: four defaulted (that is, did not return), although one of these was included in the assessment of symptoms at week 2; one was withdrawn because of patient refusal; and five were withdrawn because of violation of the protocol (two took other drugs concomitantly, one showed non-compliance, one had an oesophageal ulcer at entry to the trial, and one did not adhere to the schedule of visits). certainty that the difference in healing at four weeks between the once daily and twice daily regimens lay between 2-9 and 29 1%, indicating the direction of the difference in favour of the once daily regimen.
Assessment ofsymptoms- Table II shows the proportions of patients who experienced pain during the day and the night throughout the four weeks of treatment. No significant difference in the overall proportions of patients with pain was observed between the two regimens either The recommended dose of ranitidine for the maintenance treatment of duodenal ulceration is 150 mg at bedtime.' Ranitidine is assumed to protect the patient from relapse of ulceration by decreasing nocturnal intragastric acidity, but the effect of this dose over 24 hours is not known.
Patients, methods, and results
We studied eight men with a history of endoscopically proved duodenal ulceration on two occasions when they were in symptomatic remission-before and on the seventh day of treatment with ranitidine 150 mg at night. Their mean age was 46-5 (range 30-64) years and mean weight 75-1 (range 63-91) kg. Six were smokers and each consumed an average of 17 cigarettes during each 24 hour study period. No patient received any antisecretory drug within 14 days of the start of the study, which was approved by the hospital ethical committee. Our established technique for measuring intragastric acidity2 3 was modified to take account of the single evening maintenance dose of ranitidine: the patients were admitted to the ward at 1900, a 10 FG nasogastric tube was passed at 1915, and a standard dinner was eaten at 1930. The 24 hour study period was from 2200 until 2100 the next day. Samples of gastric juice were aspirated every hour on the hour and their acidity measured using a combined glass electrode repeatedly calibrated with standard buffers of pH 7 00, 4-01, and 1-09 (Radiometer, Copenhagen). After the first study period each patient took ranitidine 150 mg at night by mouth for seven days, the last tablet being taken at 2215 during the second study period.
Mean 24 hour intragastric acidity decreased by 42% from 42-9 mmol/l to 24-8 mmol/l (p < 0-001, two way analysis of variance). This change was due to a significant decrease in hourly intragastric acidity from 2400 to 0900 (figure). From 1000 to 2300 there was no significant change in mean hourly acidity. Median intragastric pH over 24 hours increased from pH 1x4 to pH 1x8 during maintenance treatment with ranitidine. No adverse drug effects were reported by any patient during the study.
Comment
Ranitidine 150 mg twice a day decreases both daytime and nocturnal intragastric acidity, with median 24 hour intragastric pH rising from 1-4 to 2 4 during treatment.3 This study showed that ranitidine 150 mg at night caused a decrease in acidity that was restricted to the night and early morning.
Duodenal ulceration is a chronic illness and many patients require maintenance treatment with an H2-antagonist. It is reassuring that intragastric acidity was decreased for only 10 out of 24 hours after each maintenance dose of ranitidine 150 mg at night. For most of the day and during the evening the patients receiving maintenance treatment with ranitidine showed no change in intragastric acidity. The presence of normal concentrations of acid in the stomach for this prolonged period makes bacterial colonisation of the stomach unlikely during maintenance treatment.5
It may be relevant to the pathogenesis of duodenal ulceration that the short lived decrease in nocturnal acidity observed in this study is sufficient to prevent relapse of ulceration in most patients.
There is no report of the effect of maintenance treatment with cimetidine 400 mg at night on 24 hour intragastric acidity in patients with duodenal ulcers, but its effect may be even more transient than that of ranitidine.
